SMARCB1 and rhabdoid tumor: Dual inhibition of EZH1/2 is also one of the promising therapeutic approaches for SMARCB1-deficient tumors worth exploring in future clinical practice.EZH1 and EZH2 contribute to the growth of MRT (Malignant Rhabdoid Tumor) cells and H3K27 methylation.